跳转至内容
Merck
CN

H3041

卤培米特

≥98% (HPLC)

别名:

N-(2-(4-(5-Chloro-2-oxo-1-benzimidazolinyl)piperidino)ethyl)-p-fluorobenzamide

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C21H22ClFN4O2
化学文摘社编号:
分子量:
416.88
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352204
MDL number:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

卤培米特, ≥98% (HPLC)

InChI key

NBHPRWLFLUBAIE-UHFFFAOYSA-N

SMILES string

Fc1ccc(cc1)C(=O)NCCN2CCC(CC2)N3C(=O)Nc4cc(Cl)ccc34

InChI

1S/C21H22ClFN4O2/c22-15-3-6-19-18(13-15)25-21(29)27(19)17-7-10-26(11-8-17)12-9-24-20(28)14-1-4-16(23)5-2-14/h1-6,13,17H,7-12H2,(H,24,28)(H,25,29)

assay

≥98% (HPLC)

form

powder

color

off-white

solubility

DMSO: >10 mg/mL

storage temp.

2-8°C

Quality Level

Application

Halopemide, a non-specific phospholipase D (PLD) antagonist, may be used with selective PLD antagonists (CAY10593, a PLD1 antagonist; CAY10594 or ML298, selective PLD2 antagonist) to help define the role and physiological effects regulated by phospholipase D enzymes. Halopemide may be used as the basis of the design and development of more selective PLD antagonists.

Biochem/physiol Actions

Halopemide is a dopamine receptor antagonist and a phospholipase D2 inhibitor.
Halopemide is a dopamine receptor antagonist and a phospholipase D2 inhibitor. Halopemide may be used as a screen to identify inhibitors of human PLD2 using an in vitro biochemical assay. It is also inhibitory at benzodiazepine binding sites.

pictograms

Exclamation mark

signalword

Warning

hcodes

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sarah A. Scott et al.
Probe Reports from the NIH Molecular Libraries Program (2013-06-14)
A diversity-oriented synthesis approach of the neuroleptic drug halopemide, reported to be a phospholipase D2 (PLD2) inhibitor (but later shown to be a dual PLD1/2 inhibitor) afforded ML298 (CID 53393915), a potent, >53-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC
Sarah A. Scott et al.
Probe Reports from the NIH Molecular Libraries Program (2013-06-14)
A diversity-oriented synthesis approach of the neuroleptic drug halopemide, reported to be a phospholipase D2 (PLD2) inhibitor (but later shown to be a dual PLD1/2 inhibitor) afforded ML299 (CID 56593087), a potent, dual PLD1/2 selective allosteric inhibitor (cellular PLD1, IC
M Goiny et al.
Naunyn-Schmiedeberg's archives of pharmacology, 336(1), 16-19 (1987-07-01)
Apomorphine (0.05 mg/kg intravenously) was given to conscious dogs, and gastrin levels were measured in peripheral venous blood with a radioimmunoassay. Apomorphine induced an increase of gastrin levels which peaked at 5 min. The peripheral dopamine D-2/DA2 receptor antagonist domperidone
A J Loonen et al.
Archives internationales de pharmacodynamie et de therapie, 258(1), 51-59 (1982-07-01)
Halopemide inhibits 3H-BZ binding to crude and washed rat forebrain membranes with IC50 values of 16-25 microM. Its putative metabolites are considerably less active. The actions of halopemide are probably not directly related to its ability to interfere with high-affinity
H H van Rooij et al.
Journal of chromatography, 164(2), 177-185 (1979-10-11)
Dynamic (solvent generated) cation-exchange systems for the separation of drugs and main metabolites derived from butyrophenone and diphenylpiperidine (haloperidol, pimozide, halopemide) were investigated. The effect of organic modifier, detergent, counter-ion concentration and of the pH on the retention has been

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持